Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
|Articles|May 16, 2018
IPEC-Americas Acquires Global Excipient Event
Author(s)BioPharm International Editors
ExcipientFest has been acquired by IPEC and rebranded as Excipient World.
Advertisement
The International Pharmaceutical Excipients Council of the Americas (IPEC-Americas) announced on May 8, 2018 the acquisition of the excipient event ExcipientFest, and rebranding of the event as Excipient World. The first event under the new brand, Excipient World 2019, will be held May 6–8, 2019 at the Gaylord National Resort & Convention Center at National Harbor in Maryland.
ExcipientFest was previously owned by Dwight Mutchler, president of IMCD US Pharma CMD (formerly Mutchler, Inc.), an excipient distributor. The most recent event was held in Puerto Rico on April 30–May 2, 2018.
“Dwight Mutchler and his team have done a tremendous job creating a valuable event that is internationally recognized for its quality education and sourcing opportunities,” stated Kimberly Beals, executive director of IPEC-Americas. “IPEC-Americas has been producing the conference program since 2011, so it is a natural fit to acquire the event which aligns with the organization’s mission to better serve the entire excipients industry.”
IPEC-Americas reported that the organization is working with an event consulting firm, Event Advisory Group (EAG), to rebrand the event to better address the needs of the global excipients industry, attract an expanded worldwide audience, and turn the event into a substantial non-dues revenue generator for the organization.
Source:
Advertisement
Related to this article
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
Advertisement
Advertisement
Trending on BioPharm International
1
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
4
UCB Partners With Cradle to Apply AI Across Antibody Discovery and Engineering
5